We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial Lipaemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01522482
Recruitment Status : Completed
First Posted : January 31, 2012
Last Update Posted : February 2, 2012
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Cardiovascular disease (CVD) is the greatest cause of morbidity and mortality in the UK. Abnormalities in the concentration and/or composition of lipoproteins (the lipid carrying particles), in particular low density lipoproteins (LDL) in circulation, is one of the most important physiological defects contributing to the development of CVD.

The LDL cholesterol (LDLC) response to fatty acid change is in part mediated by the APOE genotype, with E4 individuals (25% of the UK population) being most responsive to changes in dietary fats, showing greater reductions when low levels of saturated fats or fish oils are consumed and greater increases when high levels of these fats are consumed. Therefore the aims of the present study is to understand the mechanism that regulates the higher LDLC response associated with saturated fatty acids and fish oil consumption in healthy men prospectively recruited based on their APOE genotype.


Condition or disease Intervention/treatment
Cardiovascular Disease Dietary Supplement: High saturated fat meal Dietary Supplement: Saturated fatty acids and fish oil meal Dietary Supplement: High unsaturated fat meal

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Effects of Meal Fatty Acid Composition on Postprandial Lipaemia in Men According to APOE Genotype
Study Start Date : March 2009
Primary Completion Date : December 2009
Study Completion Date : July 2011
Arms and Interventions

Arm Intervention/treatment
Experimental: High saturated fat meal Dietary Supplement: High saturated fat meal
Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
Experimental: Saturated fatty acid and fish oils meal
Equivalent to two portions of oily fish
Dietary Supplement: Saturated fatty acids and fish oil meal

Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.

The dose of fish oils was equivalent to two portions of oily fish.

Active Comparator: High unsaturated fat meal
Provided a fatty acid profile representative of a typical UK diet
Dietary Supplement: High unsaturated fat meal
Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.


Outcome Measures

Primary Outcome Measures :
  1. Impact of APOE genotype and dietary fat composition in plasma lipids [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Cardiovascular disease risk factors [ Time Frame: 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Gender Male
  • Age 18-70 years
  • Body Mass Index (BMI) < 32 kg/m2
  • Plasma triglycerides 1-4 mmol/l
  • Plasma cholesterol < 8 mmol/l
  • Glucose < 7 mmol/l
  • Haemoglobin > 11 g/dl
  • ApoE E3/E3, E3/E4

Exclusion Criteria:

  • Blood pressure > 200/95 mmHg
  • Had suffered a myocardial infraction or stroke in previous 2 years.
  • Diabetes mellitus
  • Liver disease
  • Other endocrine disorders
  • Unstable angina
  • Familial hyperlipidaemia
  • Any dietary restrictions or an a weight reducing diet
  • On fatty acid supplements e.g. evening primrose oil or fish oils
  • Vigorous exercise e.g. competitive athletes
  • ApoE2/E2, apoE2/E3 and apoE2/E4
  • Any other parameter on which the investigators felt an individual was unsuitable
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01522482


Locations
United Kingdom
Department of Food and Nutritional Sciences, University of Reading
Reading, United Kingdom
Sponsors and Collaborators
University of Reading
Unilever R&D
Investigators
Principal Investigator: Julie A Lovegrove, Professor University of Reading
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Julie Lovegrove, Professor, University of Reading
ClinicalTrials.gov Identifier: NCT01522482     History of Changes
Other Study ID Numbers: 08/31
First Posted: January 31, 2012    Key Record Dates
Last Update Posted: February 2, 2012
Last Verified: January 2012

Keywords provided by Julie Lovegrove, University of Reading:
fatty acids
cardiovascular disease
genotype
apoE

Additional relevant MeSH terms:
Cardiovascular Diseases